Eli Lilly and Company (LLY) dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro. However, the drugmaker offered solid guidance for 2025, underscoring the strong growth prospects.Investors seeking to buy the dip could bet on ETFs having the largest exposure to the drugmaker. These include iShares U.S. Pharmaceuticals ETF (IHE) , Roundhill G ...

Eli Lilly and Company’s (LLY) shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. The company also issued its total revenue guidance for 2025 at the JP Morgan Healthcare Conference.Lilly’s total revenues for the fourth quarter fell short of expectations due to lower-than-expected sales of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity. In addition, lower-than-exp ...

Company Overview - Eli Lilly's stock (NYSE: LLY) experienced a decline of over 6% on January 14 due to slower than expected growth in obesity drug sales, leading to a downward adjustment of Q4 revenue forecast by 5% to $13.5 billion, which is $500 million below analysts' consensus estimate of $14 billion [1] - For the full year 2024, Eli Lilly projects revenues of $45 billion, indicating a 32% growth over 2023, but still falling short of the $45.4 billion consensus estimate [1] Future Outlook - Despite the recent stock decline, the company's outlook for 2025 is strong, with projected revenues between $58 billion and $61 billion, reflecting a 32% growth at the midpoint compared to the expected 2024 revenue [3] - Eli Lilly has a robust pipeline with drugs in clinical trials across various therapeutic areas, including a potential regulatory approval for a new weight-loss drug, orforglipron, expected next year [4] Market Performance - Eli Lilly has consistently outperformed the broader market over the past four years, with its stock generating better returns than the S&P 500 [5] - The current dip in LLY stock is viewed as an opportunity for long-term investors, with analysts estimating an average price target of $985, indicating over 30% upside from current levels [6]

Eli Lilly (LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.But over the past three months, the stock has fallen by 14% as the recent election results don't appear to be inspiring much enthusiasm around the business. Fears of heightened oversight in the industry could weigh on not just Eli Lilly, ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.The pharmaceutical giant now projects $13.5 billion in revenue for the quarter, sparking concerns over the performance of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.As of the market close on January 14, Eli Lilly’s stock was trading at $744.91, reflecting a one-day loss of over 6.5%. On the five-d ...

Company Performance and Revenue Forecast - Eli Lilly lowered its 2024 full-year revenue forecast, leading to a sharp decline in its stock price [1] - Sales of flagship weight-loss drugs Mounjaro and Zepbound grew slower than expected in Q4 2023, despite anticipated acceleration in H1 2024 [1] - The company reported Q3 2023 sales of these drugs below Wall Street's expectations, raising concerns about moderating demand [4] Stock Price Analysis and Technical Levels - Eli Lilly shares climbed 32% in 2023 but have slumped more than 16% since October 2023 [4] - Key support levels to watch are around $720 and $625, with potential entry points near these levels [5] - Important overhead resistance areas to monitor are near $860 and $965, with potential selling pressure in these regions [3][6] - The stock staged a decisive breakdown below the lower trendline of a symmetrical triangle and the 50-day MA, indicating further short-term downside potential [8][10] Market Sentiment and Trading Volume - The breakdown below the symmetrical triangle occurred on the highest trading volume day in more than two months, signaling strong selling conviction [8] - The stock could remain under scrutiny following the lowered revenue forecast and concerns about demand for its weight-loss drugs [10]

Key Points Company and Industry 1. **Company**: Eli Lilly and Company (NYSE:LLY) 2. **Event**: 43rd Annual J.P. Morgan Healthcare Conference 3. **Date**: January 14, 2025 4. **Participants**: - Dave Ricks - Chairman and CEO of Eli Lilly - Chris Schott - JPMorgan [1] Core Views and Arguments 1. **Disappointment in Meeting Expectations**: Eli Lilly acknowledges missing their own expectations but emphasizes the unprecedented nature of their business in terms of size, scale, and growth rate. 2. **Year 2024 Performance**: The company ended the year with $4 billion over their first-time guide, achieving a 32% growth rate on a strong base, with a Q4 exit growth rate of 45%. 3. **Zepbound Impact**: The launch of Zepbound contributed significantly to the company's growth during the year. [2][3] Other Important Content 1. **Learning from Challenges**: Eli Lilly acknowledges learning from their challenges in meeting expectations and aims to improve guidance for the future. 2. **Focus on Growth**: The company continues to focus on growth, leveraging the success of Zepbound and other initiatives. [2][3]

Revenue Forecast and Performance - Eli Lilly lowered its revenue forecast for the 2024 fiscal year, expecting full-year revenue of $45 billion, below the previously projected range of $45.4 billion to $46 billion [2][3] - Fourth-quarter revenue is expected to be approximately $13.5 billion, missing analysts' estimates of $13.97 billion [3] - The company's shares dropped nearly 7% to $746 in intraday trading following the announcement, despite a 17% gain over the past 12 months [6] Weight-Loss Drug Sales and Production - Sales of weight-loss drugs Mounjaro and Zepbound grew slower than expected in the fourth quarter, partly due to lower-than-expected inventory [2] - The company anticipates producing at least 60% more salable doses of these drugs in the first half of 2025 compared to 2024 [4][6] Future Outlook - Eli Lilly expects fiscal 2025 revenue to be between $58 billion and $61 billion, slightly above analysts' current projection of $59.33 billion [5] - The company plans to report fourth-quarter earnings and provide a full forecast for fiscal 2025 on February 6 [5]

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...